ABCB1 and cancer: Moreover, in the event that there are tumors harboring FGFR alterations and ABCB1 overexpression, erdafitinib would remain effective against FGFR, as we have shown that ABCB1 does not confer significant resistance to erdafitinib in cancer cells (Table 1).